降血脂剂对犬人工血管内膜增生的影响  

Effects of the lipid-lowering drugs on endothelial hyperplasia in inferior vena cava grafts in dogs

作　　者：吴爱国[1] 陈海金[1] 谭艺真[1] 姚红兵[1] 黄宗海[1] 

机构地区：[1]第一军医大学珠江医院普通外科,广东广州510282

出　　处：《第一军医大学学报》2004年第1期42-43,共2页Journal of First Military Medical University

基　　金：广东省医学科研基金资助项目(A1998365)~~

摘　　要：目的探讨降血脂剂对减轻静脉系人工血管移植物内膜增生的作用。方法将自体静脉碎片种植的Dacron植入20只犬下腔静脉(IVC),除对照组(n=8)外,实验组(n=12)术后给降血脂剂口服,两组动物定期处死,测定比较两组血中总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)含量以及人工血管内膜厚度。结果实验组血管通畅率(75%)高于对照组(37.5%),Dacron腔面术后2周完全内皮化。与对照组比较,实验组移近心端(P<0.01)、中部(P<0.05)及远心端(P<0.05)的植物内膜厚度均显著薄于对照组。动物处死时,实验组血清TC与LDL-C含量均显著低于对照组(P<0.05),HDL-C含量无组间差异(P>0.05)。结论降血脂剂可显著降低犬血脂,对减轻人工血管内膜增生、提高通畅率有一定作用。Objective To investigate the e ffects of the lipid-lowering drugs in alleviating endothelial hyperplasia in the inferior vena cava (IVC) grafts in dogs. Methods The Dacron grafts seeded with autologous venous fragments were implanted into the IVC of 20 dogs, including 12 dogs receiving oral lipid-lowering drugs serving as the treatment group and t he other 8 with-out medication as the control group. The levels of total cholest erol (TC), low-density lipoprotein cholesterol (LDL-ch) and high-density lipopr otein cholesterol (HDL-ch) in the serum were measured regularly, and all the gra fts harvested to measure the thickness of the endothelium. Results The total pa tency rate of the IVC were higher in the treatment group (75%) than in the cont rol group (37.5%), and new endothelial lining was formed two weeks after the ope ration. Compared with the control group, the endothelial thickness of the graft s at the proximal (P<0.01), middle (P<0.05) and distal segments (P<0.05) of the IVC were all smaller in the treatment group, which also had lower serum LDL-ch and TC levels (both P<0.05) but with com-parable HDL-ch levels (P>0.05). Conclus ion Administration of lipid-lowering drugs may reduce the level of serum LDL-ch and TC and the endothelial thickness of the grafts to improve the patency rate of the vessels.

关 键 词：降血脂剂 犬 人工血管 血管内膜增生 心血管药物 降血脂药物 

分 类 号：R654.4[医药卫生—外科学]